Cite
Navarro S, Quintana-Bustamante O, Sanchez-Dominguez R, et al. Preclinical studies of efficacy thresholds and tolerability of a clinically ready lentiviral vector for pyruvate kinase deficiency treatment. Mol Ther Methods Clin Dev. 2021;22:350-359doi: 10.1016/j.omtm.2021.07.006.
Navarro, S., Quintana-Bustamante, O., Sanchez-Dominguez, R., Lopez-Manzaneda, S., Ojeda-Perez, I., Garcia-Torralba, A., Alberquilla, O., Law, K., Beard, B. C., Bastone, A., Rothe, M., Villanueva, M., Ramirez, J. C., Fañanas-Baquero, S., Nieto-Romero, V., Molinos-Vicente, A., Gutierrez, S., Nicoletti, E., García-Bravo, M., Bueren, J. A., Schwartz, J. D., & Segovia, J. C. (2021). Preclinical studies of efficacy thresholds and tolerability of a clinically ready lentiviral vector for pyruvate kinase deficiency treatment. Molecular therapy. Methods & clinical development, 22350-359. https://doi.org/10.1016/j.omtm.2021.07.006
Navarro, Susana, et al. "Preclinical studies of efficacy thresholds and tolerability of a clinically ready lentiviral vector for pyruvate kinase deficiency treatment." Molecular therapy. Methods & clinical development vol. 22 (2021): 350-359. doi: https://doi.org/10.1016/j.omtm.2021.07.006
Navarro S, Quintana-Bustamante O, Sanchez-Dominguez R, Lopez-Manzaneda S, Ojeda-Perez I, Garcia-Torralba A, Alberquilla O, Law K, Beard BC, Bastone A, Rothe M, Villanueva M, Ramirez JC, Fañanas-Baquero S, Nieto-Romero V, Molinos-Vicente A, Gutierrez S, Nicoletti E, García-Bravo M, Bueren JA, Schwartz JD, Segovia JC. Preclinical studies of efficacy thresholds and tolerability of a clinically ready lentiviral vector for pyruvate kinase deficiency treatment. Mol Ther Methods Clin Dev. 2021 Jul 29;22:350-359. doi: 10.1016/j.omtm.2021.07.006. eCollection 2021 Sep 10. PMID: 34514027; PMCID: PMC8408550.
Copy
Download .nbib